Exelixis shares fell 3% after the US Food and Drug Administration extended the review period for the company's anti-cancer drugs.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.